Science Explorer Back to mapMap

Most cited papers from Hematology Oncology Consultants

What are the most cited papers from Hematology Oncology Consultants?

The most cited paper from Hematology Oncology Consultants is "Definition and classification of cancer cachexia: an international consensus" (Kenneth Fearon, Florian Strasser, Stefan D. Anker et al., 2011), with 5,828 citations. Next come "Abiraterone and Increased Survival in Metastatic Prostate Cancer" (4,448) and "Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer" (2,547).

Showing 50 of 60 papers. Every paper with more than 58 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Definition and classification of cancer cachexia: an international consensus Kenneth Fearon, Florian Strasser, Stefan D. Anker et al. · The Lancet Oncology 5 Feb 2011 5,828
2 Abiraterone and Increased Survival in Metastatic Prostate Cancer Johann Sebastian De Bono et al. · New England Journal of Medicine Open access 25 May 2011 4,448
3 Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer Mark G. Kris, Ronald B. Natale, Roy S. Herbst et al. · JAMA 22 Oct 2003 2,547
4 Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Luis G Paz-Ares et al. · The Lancet 246 authors 4 Oct 2019 2,310
5 Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Naiyer A. Rizvi et al. · The Lancet Oncology Open access 19 Feb 2015 1,436
6 Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma Sapna Pradyuman Patel et al. · New England Journal of Medicine Open access Mar 2023 893
7 Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial Jonathan Wade Goldman et al. · The Lancet Oncology Open access253 authors 4 Dec 2020 707
8 Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial Adrianus Johannes De Langen et al. · The Lancet Open access 7 Feb 2023 609
9 NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial Zev A. Wainberg, Davide Melisi, Teresa Mercade Macarulla et al. · The Lancet Open access 11 Sep 2023 504
10 Pancreatic Cancer: A Review of Current Treatment and Novel Therapies Hordur Mar Kolbeinsson, Sreenivasa Rao Chandana, Gerald Paul Wright et al. · Journal of Investigative Surgery Open access 3 Oct 2022 395
11 Effect of Prize-Based Incentives on Outcomes in Stimulant Abusers in Outpatient Psychosocial Treatment Programs Nancy M. Petry et al. · Archives of General Psychiatry Oct 2005 377
12 Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN Luis G Paz-Ares et al. · ESMO Open Open access 10 Mar 2022 349
13 Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline Susan S. Jacobs et al. · American Journal of Respiratory and Critical Care Medicine Open access Nov 2020 319
14 Effects of Lower-Cost Incentives on Stimulant Abstinence in Methadone Maintenance Treatment Jessica M. Peirce, Nancy M. Petry, Maxine L. Stitzer et al. · Archives of General Psychiatry Feb 2006 310
15 Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy David H. Henry, Naomi V. Dahl, Michael Auerbach et al. · The Oncologist Open access Feb 2007 268
16 A Study on Breath Acetone in Diabetic Patients Using a Cavity Ringdown Breath Analyzer: Exploring Correlations of Breath Acetone With Blood Glucose and Glycohemoglobin A1C Chuji Wang, Armstrong Mbi, Mark D. Shepherd · IEEE Sensors Journal 11 Dec 2009 235
17 Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine 131 I: Practice Recommendations of the American Thyroid Association John E. Freitas, Iain Ross McDougall, Lawrence T. Dauer et al. · Thyroid Open access 18 Mar 2011 234
18 Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial Hope S. Rugo, Lasika C. Seneviratne, Joseph Thaddeus Beck et al. · The Lancet Oncology 14 Mar 2017 230
19 Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression John Y. M. Koo, Lauren B. Marangell, Masaru Nakamura et al. · Journal of the European Academy of Dermatology and Venereology 6 Jul 2017 209
20 7 Intention to Treat in Clinical Trials Lloyd D. Fisher, Dennis O. Dixon, Jay Herson et al. Book chapter 19 Sep 2017 205
21 Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study Anish Thomas et al. · Journal of Thoracic Oncology Open access 8 May 2019 187
22 Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials Mark Lebwohl, Kim Alexander Papp, Lauren B. Marangell et al. · Journal of the American Academy of Dermatology 3 Oct 2017 181
23 Cooperative Regulation of Mcl-1 by Janus Kinase/STAT and Phosphatidylinositol 3-Kinase Contribute to Granulocyte-Macrophage Colony-Stimulating Factor-Delayed Apoptosis in Human Neutrophils Pearlie K. Epling‐Burnette, Bin Zhong, Fanqi Bai et al. · The Journal of Immunology Jun 2001 179
24 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting Jørn Herrstedt et al. · ESMO Open Open access 11 Jan 2024 175
25 Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case–control study Aurelius Gabriel Omlin, David E. Blum, Jan Wierecky et al. · Journal of Cachexia Sarcopenia and Muscle Open access 10 Jan 2013 160
26 Transplant Nephrectomy Improves Survival following a Failed Renal Allograft Juan Carlos Ayus, Steven G. Achinger, Shuko Lee et al. · Journal of the American Society of Nephrology Open access 29 Oct 2009 147
27 Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action Charles P. O’Brien et al. · Biological Psychiatry Nov 2004 142
28 Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer Rona D. Yaeger, Nataliya Volodymyrivna Uboha, Meredith S. Pelster et al. · Cancer Discovery Open access 8 Apr 2024 133
29 Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow-up Melinda E. Sanders, Peggy A. Schuyler, Jean F. Simpson et al. · Modern Pathology Open access 12 Dec 2014 132
30 NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup Michael W Retsky, Rick A. Rogers, Romano Demicheli et al. · Breast Cancer Research and Treatment Open access 23 May 2012 126
31 Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine Joseph A. Kwentus, Robert A. Riesenberg, Morteza Marandi et al. · Bipolar Disorders Feb 2012 126
32 Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia Gary M. Ansel, Nancy S. Sample, Charles F. Botti et al. · Catheterization and Cardiovascular Interventions 18 Dec 2003 125
33 Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review Michael W Retsky, Romano Demicheli, William J.M. Hrushesky et al. · Current Medicinal Chemistry Open access Sep 2013 122
34 Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models Delphine Lissa, Nobuyuki Takahashi, Parth Anil Desai et al. · Nature Communications Open access 19 Apr 2022 118
35 NuCLS: A scalable crowdsourcing approach and dataset for nucleus classification and segmentation in breast cancer Mohamed T. Amgad et al. · GigaScience Open access 2022 114
36 Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC) Sreenivasa Rao Chandana, Hani M. Babiker, Daruka Mahadevan · Expert Opinion on Investigational Drugs 12 Dec 2018 110
37 Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer Ryan James Hartmaier et al. · Annals of Oncology Open access 18 Jan 2018 110
38 Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer Johanna C. Bendell, John J. Nemunaitis, Sasha J. Vukelja et al. · Journal of Clinical Oncology Open access 4 Oct 2011 107
39 Mechanical Evaluation of Cross-Link Designs in Rigid Pedicle Screw Systems Jeffrey C. Dick, Thomas A. Zdeblick, Brian D. Bartel et al. · Spine Feb 1997 100
40 Eccentricity pacing of eastern equatorial Pacific carbonate dissolution cycles during the Miocene Climatic Optimum Karlos Guilherme Diemer Kochhann, Ann Holbourn, Wolfgang Kuhnt et al. · Paleoceanography 22 Aug 2016 94
41 A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma Devalingam Mahalingam, Julio Peguero, Putao Cen et al. · Cancers Open access 17 Jun 2019 92
42 Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network Robert F. Forman, Dace S. Svikis, Iván D. Montoya et al. · Journal of Substance Abuse Treatment Open access 29 Jun 2004 90
43 Epidemiology of mental health comorbidity in psoriasis Jashin J. Wu, Steven R. Feldman, John Y. M. Koo et al. · Journal of Dermatological Treatment 21 Oct 2017 89
44 Implementation of the Quality Oncology Practice Initiative at a University Comprehensive Cancer Center Douglas W. Blayney, Kristen K. McNiff, David A. Hanauer et al. · Journal of Clinical Oncology Open access 2 Jun 2009 88
45 Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma Begoña Comı́n-Anduix, Yohan Lee, Jason Jalil et al. · Journal of Translational Medicine Open access May 2008 82
46 Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models Jae Hun Shin, Hyung Bae Park, Yu Mi Oh et al. · Blood 27 Apr 2012 82
47 Percutaneous Retrograde Tibial Access in Limb Salvage Charles F. Botti, Gary M. Ansel, Mitchell Silver et al. · Journal of Endovascular Therapy Open access Jun 2003 80
48 Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies Gerald Steven Falchook et al. · Clinical Cancer Research 16 Sep 2019 79
49 Safety and Immunogenicity of Heat-Treated Zoster Vaccine (ZVHT) in Immunocompromised Adults Kathleen M. Mullane, Drew J. Winston, Michael S. Wertheim et al. · The Journal of Infectious Diseases Aug 2013 78
50 Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. C. Harris Spiridonidis, Leslie Rogers Laufman, J. B. Jones et al. · Journal of Clinical Oncology Dec 1998 72

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.